Reach-Through Rights in Biomedical Patent Licensing: A Comparative Analysis of their Anti-competitive Reach

Abstract

Medical biotechnology offers vast opportunity for the treatment of human genetic conditions, including the development and improvement of drugs, diagnostic capabilities and therapeutic techniques. Australian health and medical research has a rich and proud history. This has been recognised in numerous federal government reports, which examine the sustainability of research momentum and the ability of the Australian industry to capitalise on this research base. Australia‘s increasing $1 billion trade deficit in pharmaceuticals, medical equipment and other health and medical industries has been a major impetus for the push to develop Australia's medical research base. Many domestic and export market opportunities for the Australian biotechnology industry exist. These opportunities have been taken up for the most part by the existing research sector, and by small companies, whether spin-off companies from research institutions, or companies independently conducting research. The industry is highly competitive and motivated to participate in the biotechnology revolution on an international level. To enable them to do this, intellectual property protection is crucial as a tool to enable trade, collaboration, and competitive advantage.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 6 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.